[go: up one dir, main page]

MX2011008627A - Metodos de administracion de (4ar, 10ar)-1-n-propil-1,2,3,4,4a,5,1 0,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a traves de la mucosa oral, la mucosa nasal o la piel y composiciones farmaceuticas de los mismos. - Google Patents

Metodos de administracion de (4ar, 10ar)-1-n-propil-1,2,3,4,4a,5,1 0,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a traves de la mucosa oral, la mucosa nasal o la piel y composiciones farmaceuticas de los mismos.

Info

Publication number
MX2011008627A
MX2011008627A MX2011008627A MX2011008627A MX2011008627A MX 2011008627 A MX2011008627 A MX 2011008627A MX 2011008627 A MX2011008627 A MX 2011008627A MX 2011008627 A MX2011008627 A MX 2011008627A MX 2011008627 A MX2011008627 A MX 2011008627A
Authority
MX
Mexico
Prior art keywords
quinoline
diol
propyl
methods
pharmaceutical compositions
Prior art date
Application number
MX2011008627A
Other languages
English (en)
Inventor
Ask Pueschl
Morten Joergensen
Benny Bang-Andersen
Niels Moerk
Jennifer Larsen
Haakan Wikstroem
Thomas Nikolaj Sager
Lars Torup
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42102075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011008627(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MX2011008627A publication Critical patent/MX2011008627A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen composiciones farmacéuticas y métodos para la administración de (4aR, 10aR)-1-n-propil-1,2,3,4,4a,5,10,10a-octah idro-benzo[g]quinolin-6,7-diol o una sal farmacéuticamente aceptable del mismo y compuestos relacionados para el tratamiento de trastornos neurológicos tales como la enfermedad de Parkinson y el síndrome de las piernas inquietas.
MX2011008627A 2009-02-27 2010-02-26 Metodos de administracion de (4ar, 10ar)-1-n-propil-1,2,3,4,4a,5,1 0,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a traves de la mucosa oral, la mucosa nasal o la piel y composiciones farmaceuticas de los mismos. MX2011008627A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15594209P 2009-02-27 2009-02-27
US15595709P 2009-02-27 2009-02-27
US15593309P 2009-02-27 2009-02-27
DKPA200900279 2009-02-27
DKPA200900274 2009-02-27
DKPA200900282 2009-02-27
PCT/DK2010/050050 WO2010097091A1 (en) 2009-02-27 2010-02-26 Methods of administering (4ar, 1oar)-i-n-propyl-i, 2,3,4a7 s1io7 ioa-octahydrobenzo [g] quinoline-6,7-diol and related compounds across the oral mucosa, the nasal mucosa or the skin and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
MX2011008627A true MX2011008627A (es) 2011-09-06

Family

ID=42102075

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008627A MX2011008627A (es) 2009-02-27 2010-02-26 Metodos de administracion de (4ar, 10ar)-1-n-propil-1,2,3,4,4a,5,1 0,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a traves de la mucosa oral, la mucosa nasal o la piel y composiciones farmaceuticas de los mismos.

Country Status (17)

Country Link
US (1) US20120077836A1 (es)
EP (1) EP2400955A1 (es)
JP (1) JP2012519156A (es)
KR (1) KR20110138213A (es)
CN (1) CN102333524A (es)
AR (1) AR075626A1 (es)
AU (1) AU2010217058A1 (es)
BR (1) BRPI1006953A2 (es)
CA (1) CA2751321A1 (es)
CL (1) CL2011002100A1 (es)
CO (1) CO6410283A2 (es)
EA (1) EA201171087A1 (es)
IL (1) IL213501A0 (es)
MX (1) MX2011008627A (es)
SG (1) SG174164A1 (es)
TW (1) TW201035054A (es)
WO (1) WO2010097091A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6356795B2 (ja) * 2013-07-17 2018-07-11 ダウ グローバル テクノロジーズ エルエルシー メチルセルロースを含む粘膜適用組成物
PE20211290A1 (es) 2017-11-24 2021-07-20 H Lundbeck As Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad del parkinson
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
WO2020234276A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
US12398106B2 (en) 2019-05-21 2025-08-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson's disease
JP7641234B2 (ja) 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
US20230277697A1 (en) * 2022-03-03 2023-09-07 Serena Valentini Theragnostic method for cancer patients

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303684B1 (it) * 1998-10-30 2001-02-23 Chiesi Farma Spa Formulazioni di apomorfina in soluzione stabili nel tempo.
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥

Also Published As

Publication number Publication date
US20120077836A1 (en) 2012-03-29
WO2010097091A1 (en) 2010-09-02
CL2011002100A1 (es) 2012-06-22
IL213501A0 (en) 2011-07-31
AU2010217058A1 (en) 2011-09-08
CA2751321A1 (en) 2010-09-02
CN102333524A (zh) 2012-01-25
JP2012519156A (ja) 2012-08-23
AR075626A1 (es) 2011-04-20
TW201035054A (en) 2010-10-01
EA201171087A1 (ru) 2012-02-28
KR20110138213A (ko) 2011-12-26
BRPI1006953A2 (pt) 2016-04-26
SG174164A1 (en) 2011-10-28
EP2400955A1 (en) 2012-01-04
CO6410283A2 (es) 2012-03-30

Similar Documents

Publication Publication Date Title
MX2011008627A (es) Metodos de administracion de (4ar, 10ar)-1-n-propil-1,2,3,4,4a,5,1 0,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a traves de la mucosa oral, la mucosa nasal o la piel y composiciones farmaceuticas de los mismos.
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
WO2008154083A3 (en) Compounds, compositions and methods for the treatment of synucleinopathies
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
MX2011007774A (es) Derivados de isoxazol-isoxazol e isoxazol-isotiazol.
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
MX354423B (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
MX2011011489A (es) Derivados de isoxazol-piridina.
NZ598021A (en) Prodrugs comprising an insulin linker conjugate
WO2011047173A3 (en) Pharmaceutical compositions for oral administration
PL2229938T3 (pl) Kompozycje ezetymibu
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
WO2012007159A3 (en) Novel gastro-retentive dosage forms
MX2009006764A (es) Pirimidinonas biciclicas y usos de la misma.
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
MX2011011273A (es) Derivados de isoxazol-pirazol.
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
WO2011023367A3 (en) Bisphosphonate-prodrugs
PL2244703T3 (pl) Lekarstwo, jego wytwarzanie i zastosowanie w leczeniu bolesnych neuropatii
UA106907C2 (uk) Стабілізована фармацевтична композиція

Legal Events

Date Code Title Description
FA Abandonment or withdrawal